Selected article for: "blood draw and Discovery cohort"
Author: O’Connell, Grant C.; Treadway, Madison B.; Petrone, Ashley B.; Tennant, Connie S.; Lucke-Wold, Noelle; Chantler, Paul D.; Barr, Taura L.
Title: Peripheral blood AKAP7 expression as an early marker for lymphocyte-mediated post-stroke blood brain barrier disruption
  • Document date: 2017_4_26
    • ID: 1ey6ie95_2
    Snippet: The median time from symptom onset to blood draw across all discovery cohort subjects was 7.4 hours. In terms of clinical and demographics characteristics, patients presenting with severe HARM at 24 follow up were significantly older and displayed a higher prevalence of dyslipidemia relative to patients presenting with lower levels of HARM (Table 1) . Furthermore, a higher proportion of patients presenting with severe HARM received thrombolytic i.....
    Document: The median time from symptom onset to blood draw across all discovery cohort subjects was 7.4 hours. In terms of clinical and demographics characteristics, patients presenting with severe HARM at 24 follow up were significantly older and displayed a higher prevalence of dyslipidemia relative to patients presenting with lower levels of HARM (Table 1) . Furthermore, a higher proportion of patients presenting with severe HARM received thrombolytic intervention via recombinant tissue plasminogen activator (rtPA) than those presenting with lower levels of HARM, however this difference was not statistically significant.

    Search related documents:
    Co phrase search for related documents
    • blood symptom onset median time and symptom onset: 1, 2
    • dyslipidemia high prevalence and high prevalence: 1, 2, 3
    • high prevalence and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • high prevalence and median time: 1, 2, 3, 4, 5, 6, 7, 8
    • high prevalence and plasminogen activator: 1, 2, 3
    • high proportion and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • high proportion and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • high proportion and plasminogen activator: 1
    • low level and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • low level and plasminogen activator: 1, 2, 3, 4
    • median time and plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • median time and recombinant tissue rtPA plasminogen activator: 1
    • median time and rtPA plasminogen activator: 1
    • plasminogen activator and recombinant tissue rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • plasminogen activator and rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • recombinant tissue rtPA plasminogen activator and rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13